Business Description
Pharvaris NV
ISIN : NL00150005Y4
Share Class Description:
FRA:9EN: Ordinary SharesTotal Employee Number:
129Description
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 334.31 | |||||
Equity-to-Asset | 0.91 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -7.1 | |||||
3-Year EPS without NRI Growth Rate | -7.7 | |||||
3-Year FCF Growth Rate | -8.6 | |||||
3-Year Book Growth Rate | 1.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 29.48 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 75.1 | |||||
9-Day RSI | 71.48 | |||||
14-Day RSI | 68.61 | |||||
3-1 Month Momentum % | 20.13 | |||||
6-1 Month Momentum % | 22.3 | |||||
12-1 Month Momentum % | 63.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.24 | |||||
Quick Ratio | 11.24 | |||||
Cash Ratio | 10.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24.5 | |||||
Shareholder Yield % | -8.04 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -69.36 | |||||
ROA % | -62.8 | |||||
ROIC % | -1809 | |||||
3-Year ROIIC % | -890.45 | |||||
ROC (Joel Greenblatt) % | -12736.47 | |||||
ROCE % | -70.61 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 8.45 | |||||
Price-to-Tangible-Book | 8.43 | |||||
EV-to-EBIT | -10.83 | |||||
EV-to-Forward-EBIT | -3.79 | |||||
EV-to-EBITDA | -10.86 | |||||
EV-to-Forward-EBITDA | -9.66 | |||||
EV-to-FCF | -13.01 | |||||
| Price-to-Net-Current-Asset-Value | 8.53 | |||||
| Price-to-Net-Cash | 8.92 | |||||
Earnings Yield (Greenblatt) % | -9.23 | |||||
FCF Yield % | -7.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pharvaris NV Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.739 | ||
| Beta | 0.4844 | ||
| 3-Year Sharpe Ratio | 0.65 | ||
| 3-Year Sortino Ratio | 1.39 | ||
| Volatility % | 39.34 | ||
| 14-Day RSI | 68.61 | ||
| 14-Day ATR (€) | 1.116102 | ||
| 20-Day SMA (€) | 29.105 | ||
| 12-1 Month Momentum % | 63.55 | ||
| 52-Week Range (€) | 16.2 - 31.65 | ||
| Shares Outstanding (Mil) | 69.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pharvaris NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pharvaris NV Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 32 days | ||
| General meeting for 2026 | 2026-06-26 10:00 | 29.45 (+2.26%) | ||
| Guidance call for 2026 | 2026-05-20 11:00 | 24.60 (+1.44%) | ||
| Guidance call for 2026 | 2026-05-13 11:40 | 26.55 (+6.20%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 25.35 (+1.20%) | ||
| Annual report for 2025 | 2026-04-02 | 25.40 (+4.96%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-02 | 25.40 (+4.96%) | ||
| Guidance call for 2026 | 2026-03-11 09:20 | 21.80 (-4.39%) | ||
| The Citizens Life Sciences Conference | 2026-03-10 11:20 | 22.60 (+2.73%) |
Show
Entries
Pharvaris NV Frequently Asked Questions
What is Pharvaris NV(FRA:9EN)'s stock price today?
The current price of FRA:9EN is €30.70. The 52 week high of FRA:9EN is €31.65 and 52 week low is €16.20.
When is next earnings date of Pharvaris NV(FRA:9EN)?
The next earnings date of Pharvaris NV(FRA:9EN) is 2026-08-12 Est..
Does Pharvaris NV(FRA:9EN) pay dividends? If so, how much?
Pharvaris NV(FRA:9EN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Pharvaris NV
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers